全球急性呼吸窘迫综合征 (ARDS) 市场 – 行业趋势和 2030 年预测

急性呼吸窘迫综合征 (ARDS) 市场分析和规模

根据 2021 年 12 月发表在《肺炎》杂志上的一项名为“COVID-19 中的急性呼吸窘迫综合征：潜在原因和治疗方法”的研究，急性呼吸窘迫综合征 (ARDS) 影响了大约三分之一或 (33%) 的住院患者。此外，在重症监护病房收治的 COVID-19 患者中，75%（或近 3/4）患有 ARDS。COVID-19 患者的 ARDS 预后和死亡率并不好。因此，COVID-19 极大地影响了急性呼吸窘迫市场。因此，随着更多床位可用于治疗 ARDS 患者，预测期内将有更多医院支持细分市场扩张。

Data Bridge Market Research 分析，急性呼吸窘迫综合征 (ARDS) 市场在 2022 年的规模为 12965584 万美元，预计到 2030 年将达到 27995655 万美元，在 2023 年至 2030 年的预测期内复合年增长率为 10.1%。除了对市场价值、增长率、细分、地理覆盖范围和主要参与者等市场情景的见解外，Data Bridge Market Research 策划的市场报告还包括深度专家分析、患者流行病学、管道分析、定价分析和监管框架。

急性呼吸窘迫综合征 (ARDS) 市场范围和细分  

Market Definition

Acute respiratory distress syndrome (ARDS) is a potentially fatal lung injury that causes fluid to seep into the lungs. The majority of persons who develop ARDS are already in the hospital recovering from an injury or being treated for a condition such as COVID-19. The disease typically develops when fluids accumulate in the lungs' tiny, elastic air sacs or alveoli. Less oxygen reaches the bloodstream as a result of this fluid accumulation. The organs are deprived of getting adequate oxygen to operate normally as a result. Within a few hours to days following the initiating injury or infection, people with other illnesses will develop ARDS. Depending on the severity of the condition, a patient's chance of survival improves with age.

Acute Respiratory Distress Syndrome (ARDS) Market Dynamics

Drivers

• More Product Launches

A number of governments awareness campaigns are running to inform more people about the range of available diagnoses and treatments. Major market companies have introduced several items that have superior capabilities. For instance, in May 2021, Medtronic announced the release of the SonarMed airway monitoring system. Acoustic technology is used by this monitoring device to look for endotracheal tube occlusion. This accelerates market expansion.

• Rising need for ARDS treatment

The need for ARDS treatment is generated by an increase in hospital admissions and admissions to the critical care unit, which propels the market's expansion. 18.4% of patients with acute respiratory distress syndrome required re-hospitalization, according to a study titled "Acute respiratory distress syndrome readmissions: A countrywide cross-sectional analysis of epidemiology and costs of care" that was published in the PLOS One Journal in January 2022. Additionally, according to data from the Australian Institute of Health and Welfare published in May 2022, there were 11.8 million hospital admissions in 2020–21, an increase of 6.3% from 2019–20. Out of 11.8 million admissions, it was also reported that 7.0% of hospitalizations involved an ICU stay, 3.8% of hospitalizations involved respiratory disease, and 10.3% of hospitalizations had a separation mode indicating the patient passed away in the hospital. The market segment is anticipated to grow as a result of the rising number of admissions into emergency critical care, which creates a need for ARDS treatment.

Opportunities

• Increased Demand of Diagnosis

The market is expanding due to the increasing need for diagnoses. As many patients require several diagnoses in order for the treatment to be finished in a timely manner, the diagnosis sector is predicted to dominate the market. As a result, the market has huge opportunity.

Restraints/Challenges

• Lack of Skilled Professionals

The development of the global respiratory distress syndrome treatment market during the forecast period may be restrained by a lack of qualified specialists who are ignorant of the available treatment options for this illness.

• Increasing Cost of Treatment Therapeutics

Despite the fact that disease prevalence is rising, drug prices are also rising at the same time. These escalating treatment costs are restraining the market's expansion.

This acute respiratory distress syndrome (ARDS) market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the acute respiratory distress syndrome (ARDS) market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

COVID-19 Impact on the Acute Respiratory Distress Syndrome (ARDS) Market

The COVID-19 pandemic epidemic affected the global economy. Respiratory illnesses such as pneumonia and acute respiratory distress syndrome gradually developed due to the disease's extreme infectiousness and contagiousness throughout the pandemic and even in the post-pandemic era. As a result, the COVID-19 pandemic led to significant rise in the global market for treatments for respiratory distress syndrome.

Recent Developments

• In 2021, SonarMed airway monitoring system's introduction was announced by Medtronic. To check for endotracheal tube obstruction, the system uses acoustic technology. The company's product line has grown as a result of this.
• In 2020, The SARS-CoV-2 fast antibody test was available, according to F. Hoffman-La Roche Ltd. Together with SD Biosenseor, Inc., the experiment was started. The company's product line has grown as a result of this.

Acute Respiratory Distress Syndrome (ARDS) Market Scope

The acute respiratory distress syndrome (ARDS) market is segmented on the basis of cause, type, route of administration, end user, distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Cause

• Coronavirus Disease 2019 (COVID-19)
• Sepsis
• Inhalation of Harmful Substances
• Severe Pneumonia
• Others

Type

• Diagnosis
• Treatment

 Route of Administration

• Oral
• Parenteral
• Intramuscular
• Intravenous
• Others

 End User

• Hospitals
• Specialty Clinics
• Home Healthcare
• Others

Distribution Channel

• Direct Tender
• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

Acute Respiratory Distress Syndrome (ARDS) Market Regional Analysis/Insights

The acute respiratory distress syndrome (ARDS) market is analyzed and market size insights and trends are provided by cause, type, route of administration, end user, distribution channel as referenced above.

The countries covered in the acute respiratory distress syndrome (ARDS) market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the acute respiratory distress syndrome (ARDS) market because of recent technological advancements and the availability of numerous cutting-edge pharmacological molecules to improve the therapeutic process.

Asia-Pacific is expected to grow at the highest growth rate in the forecast period of 2023 to 2030 as a result of an increase in biotechnology research and centre activity.

报告的国家部分还提供了影响单个市场因素和国内市场监管变化，这些因素和变化会影响市场的当前和未来趋势。下游和上游价值链分析、技术趋势和波特五力分析、案例研究等数据点是用于预测单个国家市场情景的一些指标。此外，在提供国家数据的预测分析时，还考虑了全球品牌的存在和可用性以及它们因来自本地和国内品牌的激烈或稀缺竞争而面临的挑战、国内关税和贸易路线的影响。

竞争格局和急性呼吸窘迫综合征 (ARDS) 市场份额分析

急性呼吸窘迫综合征 (ARDS) 市场竞争格局按竞争对手提供详细信息。详细信息包括公司概况、公司财务状况、产生的收入、市场潜力、研发投资、新市场计划、全球影响力、生产基地和设施、生产能力、公司优势和劣势、产品发布、产品宽度和广度、应用主导地位。以上提供的数据点仅与公司对急性呼吸窘迫综合征 (ARDS) 市场的关注有关。

急性呼吸窘迫综合征 (ARDS) 市场的一些主要参与者包括：

• F. Hoffmann-La Roche Ltd（瑞士）
• 拜耳公司（德国）
• 太阳制药工业有限公司 (印度)
• 诺华公司（瑞士）
• Drägerwerk AG & Co. KGaA（德国）
• Fisher & Paykel Healthcare Limited（新西兰）
• LivaNova PLC（英国）
• 百思美健康事业股份有限公司 (台湾)
• 阿姆斯特朗医疗公司（英国）
• 辉瑞公司（美国）
• WEINMANN 急救医疗技术有限公司 + Co. KG（德国）
• 泰尔茂医疗公司（美国）
• Getinge AB.（瑞典）
• EUROSETS（意大利）

SKU-59334